Anna Truppel-Hartmann is a seasoned medical professional with over 15 years of experience in the pharmaceutical and biotechnology sectors. She earned her medical degree in Switzerland and brings a wealth of expertise and accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She has held key leadership roles at both large pharmaceutical companies and smaller biotech firms, where she successfully led clinical development programs from early-stage trials to regulatory approval and is recognized for her strategic vision coupled with strong relationships with healthcare professionals, regulatory authorities, and patient advocacy groups.
Prior to joining KSQ, Dr. Truppel-Hartmann was Senior Vice President Clinical Development and Chief Medical Officer at 2seventy bio, where she was instrumental in the development and approval of Abecma®, the first approved CAR-T therapy in multiple myeloma, and shaping the cell therapy pipeline in oncology. She held previous positions at Roche, where she led programs and high performing teams in Medical Affairs across the hemato-oncology portfolio, which resulted in successful pre- and postlaunch Medical Affairs execution of new products (Gazyva®), label extensions (MabThera®) and strategic direction for several products including, but not limited to Polivy®, Hemlibra®, Venclexta® within the pipeline. Dr. Truppel-Hartmann’s commitment to patient engagement has been another hallmark of her career, ensuring that patient voices are at the forefront of medical innovation. In addition to her medical and strategic expertise, she is passionate about talent development, mentoring the next generation of leaders in the biotech industry. Dr. Truppel-Hartmann earned her Medical Doctorate in Nuclear Medicine from the University of Zurich, Switzerland and spent part of her medical education at the University of Vienna, Austria, and the Rigshospitalet in Copenhagen, Denmark.